CompletedEUCTR 2016-000061-23
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia
This historical record does not confirm current site availability.
Historical research recordPoland + Slovakia
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
- Listed locations
- Poland · Slovakia
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 283
- Sponsor
- Sunovion Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Poland, Slovakia
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2016-000061-23
- Official title
Show the full official title
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia
Get this study by email
Recruitment & locations
CompletedPoland · Slovakia
Questions about this study
Who is behind this study?
The study sponsor is Sunovion Pharmaceuticals Inc.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy